Frequently Asked Questions
The market is segmented based on , By Type (Single Photon Emission Computed Tomography (SPECT) and Photon Emission Computed Tomography (PET)), Product (F-18, C11 and GA 68 PSMA), Application (Hospitals, Clinics and Others) – Industry Trends and Forecast to 2029.
.
The Global Prostate Cancer Nuclear Medicine Diagnostics Market size was valued at USD 389.14 USD Million in 2021.
The Global Prostate Cancer Nuclear Medicine Diagnostics Market is projected to grow at a CAGR of 11.7% during the forecast period of 2022 to 2029.
The major players operating in the market include Blue Earth Diagnostics, Lantheus, Theragnostics Ltd, Jubilant Pharma Limited, NCM, Telix Pharmaceuticals Ltd, Cardinal Health, General Electric, Bayer AG, Bracco Diagnostic , NorthStar Medical Radioisotopes, Eckert & Ziegler, Jubilant DraxImage, PharmaLogic Holdings Corp., Institute of Isotopes Co., SHINE Medical Technologies, Global Medical Solutions LLC.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
